DENVER–(BUSINESS WIRE)–#cannabis–Veriheal, health-tech industry frontrunner, released its latest cannabis statistics report which includes consumer insights and industry projections for the next five years.
The 2023 report is the first to analyze surveys completed dating back to the company’s inception in 2017. The result paints a comprehensive picture of the health goals and preferences of a staggering 1.75 million U.S. medical cannabis patients.
Projections from the 2023 report illustrate the scale of global cannabis usage, with an estimated 35.73 million users, 23.56% of whom engage in daily cannabis use. This data forecasts continued growth in the medical and recreational cannabis markets. The global cannabis market is estimated to achieve a revenue of US$51.27 billion in 2023, ultimately pointing to a market size of approximately US$102.90 billion by 2028.
The findings of the report underscore the cannabis industry’s dynamic and evolving landscape, characterized by emerging economic opportunities, growing considerations for health and wellness, and an increased need for well-balanced regulatory frameworks.
“Our cannabis report isn’t just numbers – it’s a roadmap,” said Adam Doty, Chief Technology Officer at Veriheal. “It guides towards a more informed perspective on using cannabis for wellness and enables us to envision a future where the impact of cannabis extends beyond revenue.”
For a deep dive into the findings, view the full report here.
Veriheal is a healthcare technology company that is the largest facilitator of medical marijuana cards in the nation. Its mission is to educate and advocate on behalf of patients and secure their safe access to regulated medical cannabis products. The company has a culture of open communication and transparency with its clients and operates as a concierge service to ensure HIPAA-compliant connections between patients and physicians via its proprietary platform. Visit veriheal.com for more information.